Masks and other grew 10%, outpacing devices at 6%.
Masks and other rose $50.37 M this quarter, to $539.51 M, against $489.14 M a year earlier; devices rose $39.98 M, to $720.29 M. The masks line grew faster, and it is now 43% of Sleep and Breathing Health sales, up from 42% a year earlier. Residential Care Software fell $11.12 M in the same period, so sleep products carried the total, which grew 5.9%. The MD&A says the planned discontinuation of the Astral device cut life support device sales, partially offsetting growth.
Why did masks outrun devices? The MD&A gives one shared cause for both lines: the increase in net revenue on devices and masks was primarily attributable to increased demand and unit sales across the sleep health portfolio. It does not split masks from devices, so the faster masks line goes unexplained. The filing does give regional detail: Rest of World masks grew 12%, against 10% in the Americas, and currency explains part of that gap, since at constant currency Rest of World masks grew 11%.
Put together, the growth is shifting toward masks and other, and devices, the bigger line, are growing more slowly. Devices still carry the larger dollar base, $720.29 M against $539.51 M. The gap matters because it changes which product line the company leans on as it grows, and the filing does not say which way that goes. Will masks and other keep outgrowing devices once the Astral exit is out of the base, or was this quarter's gap a one-off?

